Cathie Wood's Ark Invest Adjusts Portfolio with New AI, Tech, Biotech Investments
In its latest portfolio update, Cathie Wood’s Ark Invest added significant positions in CoreWeave (CRWV), Meta Platforms (META), and Recursion Pharmaceuticals (RXRX). The firm allocated $25.9 million to CoreWeave, a provider of AI infrastructure; $24.4 million to Meta for its digital platform exposure; and $17.6 million to biotech company Recursion. Ark Invest also added Cerebras with an investment of $16.3 million. The firm reduced holdings in Personalis (PRLS) and Toast (TOST), signaling a shift away from certain healthcare technology and restaurant software investments. These moves reflect Wood’s continued focus on high-growth sectors such as AI, digital platforms, and biotechnology, which are central to Ark Invest's long-term investment thesis. The changes in the portfolio may influence investor sentiment toward these stocks, particularly for CoreWeave and Meta, where large inflows could indicate growing confidence among growth-oriented investors.
Topics: AI infrastructure Ark Invest biotechnology digital platforms stock purchases